Prevention of chemotherapy-induced neuropathy: leukemia inhibitory factor.
van den Bent
Martin J
MJ
Neuro-oncology Unit, Daniel den Hoed Oncology Center/Erasmus University Medical Center, PO Box 5201, 3008 AE Rottterdam, Netherlands. m.vandenbent@erasmusmc.nl
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D015850:Interleukin-6 / Q000627:therapeutic use*; D053605:Leukemia Inhibitory Factor; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced* / Q000517:prevention & control*; D011506:Proteins / Q000627:therapeutic use*; D016896:Treatment Outcome
D015850:Interleukin-6; C507837:LIF protein, human; D053605:Leukemia Inhibitory Factor; D011506:Proteins; D016190:Carboplatin; D017239:Paclitaxel